The assets include Maxygen‘s drug candidate, MAXY-VII, to treat the blood-clotting disorder hemophilia. MAXY-VII is expected to enter early-stage trials in the third quarter of 2008, the company said in a statement.
The deal includes a license to use Maxygen’s MolecularBreeding technology, used to target genes. (Reuters)
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
